These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25936315)

  • 21. Plasma exchange in neurological disease.
    Osman C; Jennings R; El-Ghariani K; Pinto A
    Pract Neurol; 2020 Apr; 20(2):92-99. PubMed ID: 31300488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of therapeutic plasma exchange in pediatric neurology: a single-center experience.
    Özkale M; Erol I; Özkale Y; Kozanoğlu İ
    Acta Neurol Belg; 2018 Sep; 118(3):451-458. PubMed ID: 29882008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic Apheresis in Neurological Disorders].
    Nakatsuji Y
    Brain Nerve; 2021 May; 73(5):425-430. PubMed ID: 34006672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABO-incompatible kidney transplantation using regenerative selective immunoglobulin adsorption.
    Teschner S; Stippel D; Grunenberg R; Beck B; Wahba R; Gathof B; Benzing T; Burst V
    J Clin Apher; 2012; 27(2):51-60. PubMed ID: 22271603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The course of anticardiolipin antibody levels under immunoadsorption therapy.
    Hauser AC; Hauser L; Pabinger-Fasching I; Quehenberger P; Derfler K; Hörl WH
    Am J Kidney Dis; 2005 Sep; 46(3):446-54. PubMed ID: 16129206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption.
    Marn Pernat A; Buturović-Ponikvar J; Svigelj V; Ponikvar R
    Ther Apher Dial; 2009 Aug; 13(4):310-3. PubMed ID: 19695065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tryptophan immunoadsorption for the treatment of autoimmune encephalitis.
    Köhler W; Ehrlich S; Dohmen C; Haubitz M; Hoffmann F; Schmidt S; Klingel R; Kraft A; Neumann-Haefelin T; Topka H; Stich O; Baumgartner A; Fassbender C
    Eur J Neurol; 2015 Jan; 22(1):203-6. PubMed ID: 24589025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmapheresis for neurological disorders.
    Schröder A; Linker RA; Gold R
    Expert Rev Neurother; 2009 Sep; 9(9):1331-9. PubMed ID: 19769448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
    Pták J
    Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic plasma exchange in neurological disorders: Experience from a tertiary neuroscience centre.
    Das J; Chauhan VD; Mills D; Johal NJ; Tan M; Matthews R; Keh R; Lilleker JB; Gosal D; Sharaf N
    Transfus Apher Sci; 2019 Dec; 58(6):102654. PubMed ID: 31648858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In-vitro and in-vivo studies on the selective immunoadsorption treatment of neurological diseases].
    Heininger K
    Schriftenr Neurol; 1993; 33():1-91. PubMed ID: 8327864
    [No Abstract]   [Full Text] [Related]  

  • 32. Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis.
    Kaya E; Keklik M; Sencan M; Yilmaz M; Keskin A; Kiki I; Erkurt MA; Sivgin S; Korkmaz S; Okan V; Doğu MH; Unal A; Cetin M; Altuntaş F; Ilhan O
    Transfus Apher Sci; 2013 Jun; 48(3):349-52. PubMed ID: 23619327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of antibody-mediated rejection including immunoadsorption during first year after renal transplantation--Clinical results and regulation of endothelial progenitor cells.
    Opgenoorth M; Wagner A; Passauer J; Hohenstein B; Hugo C
    Atheroscler Suppl; 2015 May; 18():67-73. PubMed ID: 25936307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?
    Schmaldienst S; Müllner M; Goldammer A; Spitzauer S; Banyai S; Hörl WH; Derfler K
    Rheumatology (Oxford); 2001 May; 40(5):513-21. PubMed ID: 11371659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma C3c in immune-mediated neurological diseases: a preliminary report.
    Kamolvarin N; Hemachudha T; Ongpipattanakul B; Phanthumchinda K; Sueblinvong T
    Acta Neurol Scand; 1991 Jun; 83(6):382-7. PubMed ID: 1716038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial.
    Greinacher A; Friesecke S; Abel P; Dressel A; Stracke S; Fiene M; Ernst F; Selleng K; Weissenborn K; Schmidt BM; Schiffer M; Felix SB; Lerch MM; Kielstein JT; Mayerle J
    Lancet; 2011 Sep; 378(9797):1166-73. PubMed ID: 21890192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues.
    Gold R; Stangel M; Dalakas MC
    Nat Clin Pract Neurol; 2007 Jan; 3(1):36-44. PubMed ID: 17205073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness.
    Klingele M; Allmendinger C; Thieme S; Baerens L; Fliser D; Jan B
    Sci Rep; 2020 May; 10(1):7925. PubMed ID: 32404917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
    Köhler W; Bucka C; Klingel R
    J Clin Apher; 2011 Dec; 26(6):347-55. PubMed ID: 22095647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful immunoadsorption with membrane plasmapheresis for multiple sclerosis.
    Hosokawa S; Oyamaguchi A; Yoshida O
    ASAIO Trans; 1989; 35(3):576-7. PubMed ID: 2688722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.